NASDAQ:AMRNAmarin Competitors & Alternatives

Dr.Reddy's Laboratories (NYSE:RDY) and Amarin (NASDAQ:AMRN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility and Risk

Dr.Reddy's Laboratories has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.

Institutional & Insider Ownership

12.9% of Dr.Reddy's Laboratories shares are held by institutional investors. Comparatively, 44.4% of Amarin shares are held by institutional investors. 2.0% of Dr.Reddy's Laboratories shares are held by insiders. Comparatively, 2.8% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Dr.Reddy's Laboratories and Amarin's gross revenue, earnings per share and valuation.

Dr.Reddy's Laboratories has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Dr.Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dr.Reddy's Laboratories and Amarin's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Dr.Reddy's Laboratories and Amarin, as provided by MarketBeat.com.

Amarin has a consensus price target of $17.2308, suggesting a potential upside of 146.86%. Given Amarin's higher probable upside, analysts clearly believe Amarin is more favorable than Dr.Reddy's Laboratories.

Summary

Dr.Reddy's Laboratories beats Amarin on 8 of the 14 factors compared between the two stocks.

Elanco Animal Health (NYSE:ELAN) and Amarin (NASDAQ:AMRN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility and Risk

Elanco Animal Health has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.

Institutional & Insider Ownership

44.4% of Amarin shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by insiders. Comparatively, 2.8% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Elanco Animal Health and Amarin's gross revenue, earnings per share and valuation.

Elanco Animal Health has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elanco Animal Health and Amarin's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Elanco Animal Health and Amarin, as provided by MarketBeat.com.

Elanco Animal Health currently has a consensus price target of $29.20, suggesting a potential upside of 34.19%. Amarin has a consensus price target of $17.2308, suggesting a potential upside of 146.86%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Elanco Animal Health.

Summary

Amarin beats Elanco Animal Health on 8 of the 14 factors compared between the two stocks.

Ionis Pharmaceuticals (NASDAQ:IONS) and Amarin (NASDAQ:AMRN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility and Risk

Ionis Pharmaceuticals has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.

Institutional & Insider Ownership

84.0% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 44.4% of Amarin shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Ionis Pharmaceuticals and Amarin's gross revenue, earnings per share and valuation.

Ionis Pharmaceuticals has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ionis Pharmaceuticals and Amarin's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Ionis Pharmaceuticals and Amarin, as provided by MarketBeat.com.

Ionis Pharmaceuticals currently has a consensus price target of $74.8571, suggesting a potential upside of 23.17%. Amarin has a consensus price target of $17.2308, suggesting a potential upside of 146.86%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Ionis Pharmaceuticals.

Summary

Ionis Pharmaceuticals beats Amarin on 9 of the 13 factors compared between the two stocks.

Mylan (NASDAQ:MYL) and Amarin (NASDAQ:AMRN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility and Risk

Mylan has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.

Institutional & Insider Ownership

85.5% of Mylan shares are held by institutional investors. Comparatively, 44.4% of Amarin shares are held by institutional investors. 0.6% of Mylan shares are held by insiders. Comparatively, 2.8% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Mylan and Amarin's gross revenue, earnings per share and valuation.

Mylan has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Mylan, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mylan and Amarin's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Mylan and Amarin, as provided by MarketBeat.com.

Mylan currently has a consensus price target of $23.75, suggesting a potential upside of 49.09%. Amarin has a consensus price target of $17.2308, suggesting a potential upside of 146.86%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Mylan.

Summary

Mylan beats Amarin on 8 of the 14 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Amarin (NASDAQ:AMRN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility and Risk

ACADIA Pharmaceuticals has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ACADIA Pharmaceuticals and Amarin, as provided by MarketBeat.com.

ACADIA Pharmaceuticals currently has a consensus price target of $56.50, suggesting a potential upside of 5.23%. Amarin has a consensus price target of $17.2308, suggesting a potential upside of 146.86%. Given Amarin's higher probable upside, analysts clearly believe Amarin is more favorable than ACADIA Pharmaceuticals.

Valuation & Earnings

This table compares ACADIA Pharmaceuticals and Amarin's gross revenue, earnings per share and valuation.

Amarin has higher revenue and earnings than ACADIA Pharmaceuticals. Amarin is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

97.8% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 44.4% of Amarin shares are held by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares ACADIA Pharmaceuticals and Amarin's net margins, return on equity and return on assets.

Summary

Amarin beats ACADIA Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Amarin (NASDAQ:AMRN) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.

Risk & Volatility

Amarin has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Amarin and Perrigo, as provided by MarketBeat.com.

Amarin currently has a consensus price target of $17.2308, suggesting a potential upside of 146.86%. Perrigo has a consensus price target of $58.4286, suggesting a potential upside of 5.68%. Given Amarin's stronger consensus rating and higher probable upside, analysts plainly believe Amarin is more favorable than Perrigo.

Valuation and Earnings

This table compares Amarin and Perrigo's gross revenue, earnings per share and valuation.

Perrigo has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

44.4% of Amarin shares are owned by institutional investors. Comparatively, 83.9% of Perrigo shares are owned by institutional investors. 2.8% of Amarin shares are owned by insiders. Comparatively, 0.3% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Amarin and Perrigo's net margins, return on equity and return on assets.

Summary

Perrigo beats Amarin on 8 of the 14 factors compared between the two stocks.